Business

Moderna shares double on melanoma vaccine trial success

Financial Times · 19 August 2026 at 16:44

Moderna shares double on melanoma vaccine trial success

Drugmaker’s cancer shot developed with Merck delivers positive outcome in late-stage trial

Read the full article on Financial Times ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.ft.com — the content belongs to Financial Times.

Moderna shares double on melanoma vaccine trial success

More from Financial Times

Moderna’s cancer shot: exciting for investors, inconclusive for patients

US Treasury to double buybacks of long-term government debt

Zelenskyy fires top aide as corruption allegations pile up

Europe should wish Marco Rubio a bright future

More in Business

Monzo banking app is down leaving some customers unable to access accounts

Moderna’s cancer shot: exciting for investors, inconclusive for patients

From pillow speakers to acoustic headbands, five weird sleep products our writers have tested

Average house price is up £5,000 in the year to June - but in one London borough they've fallen £291,000...

We ditched our stable nine-to-five jobs to sell coins and bullion online and now both earn £50,000 a year. This is how to tell if you are (literally) sitting on a goldmine

US Treasury to double buybacks of long-term government debt